Key result
Aldosterone receptor antagonists, including spironolactone and eplerenone, reduce mortality and hospitalizations across a spectrum of patients with systolic heart failure.
Why the study?
Do aldosterone receptor antagonists reduce death in patients with systolic heart failure?
Do aldosterone receptor antagonists reduce death in patients with systolic heart failure?
Aldosterone receptor antagonists are an effective standard therapy for reducing mortality in systolic heart failure, though their comparative efficacy and role in diastolic heart failure remain to be fully elucidated.
The aldosterone receptor antagonists (ARAs) spironolactone (Aldactone) and eplerenone (Inspra) have become part of standard medical therapy for heart failure, having shown clinical efficacy in randomized trials in patients with advanced symptomatic systolic heart failure, postinfarction heart failure with cardiac dysfunction, and systolic heart failure with mild symptoms. The benefits include a lower rate of death. Yet to be answered is whether the two drugs are clinically equivalent; another question is whether they may benefit everyone with symptomatic heart failure, including diastolic heart failure.
No takes yet. Share an insight, caveat, or question.
Nagarajan et al. (2012) conducted a review in Heart failure. Aldosterone receptor antagonists (spironolactone and eplerenone) vs. Standard medical therapy / Placebo was evaluated. Aldosterone receptor antagonists, including spironolactone and eplerenone, reduce mortality and hospitalizations across a spectrum of patients with systolic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: